Exelixis | EXEL - Ebit


Exelixis reported $256.36M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Agios Pharmaceuticals USD -116.87M 10.19M Sep/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD -1.5B 5.01B Sep/2025
Bayer EUR -399M 363M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Bristol-Myers Squibb USD 4.04B 1.78B Sep/2025
Cytokinetics USD -166.76M 55.25M Sep/2025
Eisai JPY 13.67B 7.07B Sep/2025
Eli Lilly USD 7.02B 3.32B Jun/2025
Exelixis USD 256.36M 42.78M Sep/2025
Genmab DKK 432M 900.27M Jun/2025
Glaxosmithkline GBP 3.76B 1.69B Sep/2025
Incyte USD 431.31M 120.49M Sep/2025
Ionis Pharmaceuticals USD -160.18M 304.96M Sep/2025
MacroGenics USD 20.16M 55.51M Sep/2025
Merck USD 6.24B 1.32B Dec/2025
Moderna USD -260M 557M Sep/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Novartis USD -9.19B 13.87B Jun/2025
Pfizer USD 4.65B 71M Dec/2025
Sanofi EUR 3.74B 2.23B Sep/2025
Takeda JPY 257.49B 568.56B Dec/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
Xencor USD -47.52M 24.69M Sep/2025